New asthma drug shows promise in early safety trial

NCT ID NCT04007198

Completed Disease control Sponsor: Biocon Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a drug called itolizumab (EQ001) in 18 adults with moderate-to-severe asthma that is not well controlled by standard treatments. The main goal was to see if the drug is safe and how the body processes it. Researchers also looked for early signs that it might help control asthma symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Itolizumab (EQ001), a drug given by infusion
What this could lead to: If it works, this could point toward a new treatment option for people with hard-to-control asthma.
What could go wrong: This is a very early, small Phase 1 trial with only 18 people. It mainly checks safety, not whether the drug actually helps asthma. Many early-stage drugs fail to show benefit in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

Box Hill Hospital

Box Hill, Australia
Dunedin Hospital

Dunedin, New Zealand
Flinders Medical Centre

Adelaide, Australia
Medical Research Institute of New Zealand

Wellington, New Zealand
Melbourne Health

Parkville, Australia
Monash Medical Centre

Clayton, Australia
Paratus Clinical Research Central Coast

Kanwal, Australia
Paratus Clinical Research Western Sydney

Sydney, Australia
Respiratory Clinical Trials

Kent Town, Australia
Respiratory Research, Greenland Clinical Centre

Auckland, New Zealand
The New Zealand Respiratory & Sleep Institute

Greenlane, New Zealand
The Queen Elizabeth Hospital

Woodville, Australia
TrialsWest

Murdoch, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.